nanoBiTE mRNA

Bispecific T-cell engagers (BiTEs) are innovative immunotherapies that redirect T cells to eliminate tumor cells by simultaneously binding a tumor-associated antigen and a T cell specific protein. Traditional bispecific T cell engager (BiTE) antibody relies on cumbersome in vitro expression system for scaled-up production and closely monitored intravenous injection into a mammalian host. To overcome these obstacles, nanoBiTE mRNA is a new and emergent biologic which can be delivered intramuscularly into the host and produces the antibody in vivo by utilizing the muscle as a protein production factory.

Abnova’s nanoBiTE mRNA service integrates its NanoAb™ VHH antibody, mRNA IVT technology, and lipid nanoparticle (LNP) delivery. This approach allows in vivo delivery of BiTE instructions to the muscle cells via mRNA encapsulated ionizable lipid nanoparticles. Unlike conventional BiTE therapies which use large IgG framework of monoclonal antibodies, Abnova incorporates smaller, covalently linked VHH antibodies for tumor antigen binding and T cell protein targeting resulting in higher sensitivity and specificity. The smaller size also allows improved tissue penetration into the tumor microenvironment for better treatment efficacy.

With expertise not only in VHH antibodies but also in nanoBiTE vector design, codon optimization, mRNA modification and purification, Abnova provides a flexible and scalable nanoBiTE for in vivo production which obviates complex manufacturing, higher cost, and invasive administration. nanoBiTE mRNA is an efficient and versatile platform for diverse applications in cancer immunotherapy.